// App-Quantinova.ai

CT244 : A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Researchers

Presenter

  • Grace K. Dy

Principal Investigators

  • Diwakar Davar

  • Evanthia Galanis

  • Danielle Townsley

  • Djuro Karanovic

  • Maria Schwaederle

  • Beth Kelly

  • Dmitriy Zamarin

  • Mitesh Borad

  • Kevin Harrington

Medical Centers

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • Mayo Clinic, Rochester, MN

  • AstraZeneca, Gaithersburg, MD

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Mayo Clinic, Scottsdale, AZ

  • Institute for Cancer Research, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Non Small Cell Lung cancer

  • Liver cancer

  • Squamous cell carcinoma

  • Small cell lung cancer

  • Solid malignancies

  • Renal cell carcinoma

  • Colorectal Cancer

  • Breast cancer

  • Lung Cancer

  • Melanoma

Biomarkers

  • Granulocyte-macrophage-colony stimulating factor

Drug/Treatment

  • Durvalumab

  • GM-CSF

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT03889275

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved